DOP2020000148A - Inhibidores de cd73 - Google Patents

Inhibidores de cd73

Info

Publication number
DOP2020000148A
DOP2020000148A DO2020000148A DO2020000148A DOP2020000148A DO P2020000148 A DOP2020000148 A DO P2020000148A DO 2020000148 A DO2020000148 A DO 2020000148A DO 2020000148 A DO2020000148 A DO 2020000148A DO P2020000148 A DOP2020000148 A DO P2020000148A
Authority
DO
Dominican Republic
Prior art keywords
inhibitors
pyridazin
dione
pyrimidine
cycloalkyl
Prior art date
Application number
DO2020000148A
Other languages
English (en)
Inventor
Wang Yan
Cristina Garcia Paredes Maria
Zhao Genshi
Dean Dally Robert
Marie Howell Jennifer
George Njoroge Frank
Joseph Ii Heinz Lawrence
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2020000148A publication Critical patent/DOP2020000148A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona 5-[5]-[2-cicloalquil]-6-piridazin-3-il]-1H-pirimidin-2,4-diona, o sales aceptables desde el punto de vista farmacéutico de este, que inhiben la actividad de CD73 y son útiles en el tratamiento contra el cáncer.
DO2020000148A 2018-03-01 2020-07-28 Inhibidores de cd73 DOP2020000148A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862636978P 2018-03-01 2018-03-01
US201862775553P 2018-12-05 2018-12-05
PCT/US2019/019074 WO2019168744A1 (en) 2018-03-01 2019-02-22 Cd73 inhibitors

Publications (1)

Publication Number Publication Date
DOP2020000148A true DOP2020000148A (es) 2020-09-15

Family

ID=65686120

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2020000148A DOP2020000148A (es) 2018-03-01 2020-07-28 Inhibidores de cd73

Country Status (33)

Country Link
US (1) US11028074B2 (es)
EP (1) EP3759096B1 (es)
JP (1) JP6794560B2 (es)
KR (1) KR20200116965A (es)
CN (1) CN111819173B (es)
AU (1) AU2019228473B2 (es)
BR (1) BR112020016066A2 (es)
CA (1) CA3092661C (es)
CL (1) CL2020002158A1 (es)
CO (1) CO2020010191A2 (es)
CR (1) CR20200376A (es)
CY (1) CY1125145T1 (es)
DK (1) DK3759096T3 (es)
DO (1) DOP2020000148A (es)
EC (1) ECSP20052897A (es)
ES (1) ES2909701T3 (es)
HR (1) HRP20220459T1 (es)
IL (1) IL277006B2 (es)
JO (1) JOP20200209A1 (es)
LT (1) LT3759096T (es)
MA (1) MA52413A (es)
MX (1) MX2020009115A (es)
PE (1) PE20210177A1 (es)
PH (1) PH12020551464A1 (es)
PL (1) PL3759096T3 (es)
PT (1) PT3759096T (es)
RS (1) RS63073B1 (es)
SG (1) SG11202008366RA (es)
SI (1) SI3759096T1 (es)
TW (1) TWI702954B (es)
UA (1) UA123890C2 (es)
WO (1) WO2019168744A1 (es)
ZA (1) ZA202004805B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022001365A2 (pt) * 2019-08-29 2022-06-07 Lilly Co Eli Formas cristalinas de um inibidor de cd73
WO2021113625A1 (en) * 2019-12-06 2021-06-10 Plexxikon Inc. Compounds and methods for cd73 modulation and indications therefor
JP2023522949A (ja) 2020-04-23 2023-06-01 オプナ バイオ ソシエテ アノニム Ｃｄ７３調節のための化合物及び方法並びにそれらの表示
CR20220547A (es) * 2020-05-01 2022-12-15 Gilead Sciences Inc Compuestos de 2,4-dioxopirimidina inhibidores de cd73
CN115702150A (zh) * 2020-07-07 2023-02-14 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
CA3191829A1 (en) 2020-09-08 2022-03-17 Hao Wu Cd73 inhibitor and application thereof in medicine
CN114315839A (zh) * 2020-09-30 2022-04-12 武汉人福创新药物研发中心有限公司 嘧啶二酮类化合物及其用途
WO2022090711A1 (en) 2020-10-26 2022-05-05 AdoRx Therapeutics Limited Compounds as cd73 inhibitors
WO2022095975A1 (zh) 2020-11-05 2022-05-12 武汉人福创新药物研发中心有限公司 Cd73抑制剂及其应用
CN114437038A (zh) * 2020-11-05 2022-05-06 武汉人福创新药物研发中心有限公司 哒嗪炔烃类化合物及其用途
WO2022121914A1 (zh) * 2020-12-10 2022-06-16 上海翰森生物医药科技有限公司 氧代氮环类衍生物调节剂、其制备方法和应用
WO2022195499A1 (en) * 2021-03-19 2022-09-22 Aurigene Discovery Technologies Limited Substituted pyridazine compounds as cd73 inhibitors
CA3235986A1 (en) 2021-10-29 2023-05-04 Gilead Science, Inc. Cd73 compounds
WO2023169327A1 (zh) * 2022-03-07 2023-09-14 贝达药业股份有限公司 一种哒嗪类衍生物的晶型、制备方法及其应用
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2024006929A1 (en) * 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024013206A1 (en) * 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Heterocycle compounds for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2434337T3 (es) 2006-04-03 2013-12-16 Glaxo Group Limited Derivados de azabiciclo[3.1.0]hexilo como moduladores de los receptores D3 de la dopamina
EP1860113A1 (en) * 2006-05-24 2007-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Ectonucleotidase inhibitors
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
UA124529C2 (uk) * 2016-01-08 2021-10-05 Аркус Байосайєнсіз, Інк. Модулятори екто-5-нуклеотидази та їх застосування
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives

Also Published As

Publication number Publication date
CL2020002158A1 (es) 2020-11-13
EP3759096A1 (en) 2021-01-06
CA3092661C (en) 2022-07-12
CN111819173B (zh) 2023-06-06
CA3092661A1 (en) 2019-09-06
CO2020010191A2 (es) 2020-08-31
PT3759096T (pt) 2022-03-30
DK3759096T3 (en) 2022-03-07
ZA202004805B (en) 2022-01-26
JP2020517655A (ja) 2020-06-18
WO2019168744A1 (en) 2019-09-06
SI3759096T1 (sl) 2022-07-29
US20210002257A1 (en) 2021-01-07
TW201945002A (zh) 2019-12-01
MA52413A (fr) 2021-01-06
ES2909701T3 (es) 2022-05-10
SG11202008366RA (en) 2020-09-29
TWI702954B (zh) 2020-09-01
AU2019228473A1 (en) 2020-08-20
KR20200116965A (ko) 2020-10-13
CN111819173A (zh) 2020-10-23
RS63073B1 (sr) 2022-04-29
IL277006B2 (en) 2023-03-01
CY1125145T1 (el) 2024-02-16
UA123890C2 (uk) 2021-06-16
US11028074B2 (en) 2021-06-08
PE20210177A1 (es) 2021-01-29
PH12020551464A1 (en) 2021-09-01
AU2019228473B2 (en) 2021-02-25
IL277006B (en) 2022-11-01
HRP20220459T1 (hr) 2022-05-27
BR112020016066A2 (pt) 2020-12-08
JOP20200209A1 (ar) 2020-08-30
ECSP20052897A (es) 2020-09-30
LT3759096T (lt) 2022-04-11
PL3759096T3 (pl) 2022-05-09
IL277006A (en) 2020-10-29
JP6794560B2 (ja) 2020-12-02
MX2020009115A (es) 2022-11-15
CR20200376A (es) 2020-10-23
EP3759096B1 (en) 2022-02-16

Similar Documents

Publication Publication Date Title
ECSP20052897A (es) Inhibidores de cd73
ECSP19033052A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
ECSP19032676A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
CL2019001551A1 (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2018001753A1 (es) Composiciones para modular la expresión de c9orf72 (divisional solicitud 201600839)
EA201990202A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
CL2017001362A1 (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática
UY35834A (es) Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
CL2018002698A1 (es) Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
CL2019002854A1 (es) Compuesto macrocíclico y sus usos.
MX2020003868A (es) Compuesto heterociclico como inhibidor de proteina quinasa.
CL2017001209A1 (es) Inhibidor de cinasa aurora a
BR112020016929A8 (pt) Métodos de uso para derivados de benzotriazol trissubstituídos
WO2016198698A8 (en) P38 inhibitors for the treatment and prophylaxis of liver cancer
ZA202003281B (en) Heterocycle substituted pyridine derivative antifungal agents
CO2017009182A2 (es) Cepas bacterianas productoras de histamina para tratamiento del cáncer
CO2022000270A2 (es) Inhibidores de enzimas
CO2021008535A2 (es) Compuestos de quinolina como inhibidores de quinasas tam y met
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CL2016003271A1 (es) Métodos para tratar infecciones
EA202091821A1 (ru) Ингибиторы cd73
CL2019001046A1 (es) Terapia de combinación que incluye un inhibidor mdm2 y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cáncer. (divisional solicitud 201601131)
MA53225A (fr) Agents inhibiteurs d'ask1